BackXenetic Biosciences- Warrants (19/07/2024) Overview
Xenetic Biosciences Inc - Warrants (19/07/2024)

Xenetic Biosciences- Warrants (19/07/2024) Return on Equity

Xenetic Biosciences- Warrants (19/07/2024) (XBIOW) has a ROE of -40.76%, below the Healthcare sector average of 21.3%.

Get informed when a big investor buys or sells

+ Follow

ROE

-40.76%

Return on Equity

-40.76%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Xenetic Biosciences- Warrants (19/07/2024) (XBIOW) FAQ

The latest ROE for XBIOW is -40.76%. That is below the Healthcare sector average of 21.3%. Investors often review this figure alongside Xenetic Biosciences- Warrants (19/07/2024)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, XBIOW currently prints -40.76% for ROE, while the sector average sits near 21.3%. That is roughly 291.3% below the sector mean. Large gaps often invite a closer look at Xenetic Biosciences- Warrants (19/07/2024)'s growth, margins, and balance sheet.

Return on Equity shows how effectively Xenetic Biosciences- Warrants (19/07/2024) converts resources into returns. At -40.76%, XBIOW may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XBIOW's ROE (-40.76%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Xenetic Biosciences- Warrants (19/07/2024)'s ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.